Skip to main content
OpenTrials
Completed

NCT Number: NCT00218348

Treatment of Cocaine Dependence: Comparison of Three Doses of Dextro-Amphetamine Sulfate and Placebo

Dextro-amphetamine sulfate is a central nervous system stimulant that increases the release of the neurotransmitter dopamine in the brain. The purpose of this study is to further examine dose ranges of dextro-amphetamine sulfate as a treatment for cocaine dependence.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cocaine-Related Disorders Chemically-Induced Disorders Mental Disorders Substance-Related Disorders

Age range

25 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

The University of Texas Health Science Center at Houston

Houston, Texas, 77030, United States

About this study

This randomized, double-blind dose study will compare the effectiveness of three active medication doses of dextro-amphetamine sulfate to placebo in the treatment of cocaine dependence. Participants will be randomly assigned to one of the four following dosages of dextro-amphetamine sulfate: 0 mg, 40 mg, 60 mg, or 80 mg. Participants will undergo a 2-week stabilization period followed by a 25-week study period. The study period will include administration of the stable medication dose for 21 weeks, followed by 1 week of dose reduction, and then 3 weeks without medication. All participants will receive weekly cognitive behavioral therapy and electrocardiograms. Participants will be given the option to participate in a voluntary plasma blood draw during Weeks 4, 8, and 20 and will be scheduled for follow-up assessments at Months 1 and 3 post-treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • DSM-IV diagnosis of cocaine dependence, as determined by the Structured Clinical Interview for DSM-IV
  • Agreement to use an adequate method of contraception for the duration of the study
  • Electrocardiogram confirmation by a cardiologist
  • Cocaine-positive urine test prior to study entry

Exclusion criteria

  • High blood pressure
  • Significant heart disease
  • Clinically significant cardiovascular abnormality
  • Angina
  • Kidney, liver, or gastrointestinal disorder
  • Current Axis I disorder not related to drug use
  • Current dependence on any drug other than nicotine
  • Attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD)
  • On probation or parole for reasons other than those related to drug abuse charges
  • Pregnant or breastfeeding
  • Sought treatment for drug dependence within 3 months prior to study entry
  • Currently taking prescribed medications

Treatment and study plan

Dextro-Amphetamine Sulfate

Drug

Primary outcomes

  1. Substance use and retention

Secondary outcomes

  1. Effectiveness measures, including psycho-social variables, side effects, and self-reported measures

Sponsors and collaborators

Lead sponsor

The University of Texas Health Science Center, Houston

Other

Collaborators

  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

Pharmacotherapy for Cocaine Dependence - 1

Important dates

Study start
2003
Primary completion
2007
Study completion
2007
First posted
Sep 22, 2005
Registry last updated
Dec 19, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.